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Background: Interleukin-37 (IL-37), a new member of IL-1 family cytokine, is recently identified as a natural inhibitor
of innate immunity. This study aimed to measure the peripheral blood mononuclear cells (PBMCs) and serum levels
of IL-37 in patients with systemic lupus erythematosus (SLE) and to investigate its role in SLE, including its correlation
with disease activity, organ disorder and the regulation of inflammatory cytokines.
Methods: The expressions of IL-37 mRNAs in PBMCs and serum IL-37 levels in 66 SLE patients were measured by
real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). SLE patients PBMCs were
stimulated with recombinant IL-37, levels of cytokines TNF-α, IL-1β, IL-6 and IL-10 were detected by RT-PCR and ELISA.
Results: IL-37 mRNAs and serum protein levels were higher in patients with SLE compared with healthy controls. Patients
with active disease showed higher IL-37 mRNAs and serum protein levels compared with those with inactive disease as
well as healthy controls. Serum IL-37 levels correlated with SLEDAI and inversely with C3 and C4. Serum IL-37 levels were
higher in SLE patients with renal involvement compared with those without renal disease. In vitro, IL-37 inhibited
the production of TNF-α, IL-1β and IL-6 in PBMCs of patients with SLE, whereas the production of IL-10 was unaffected.
Conclusions: IL-37 associated with SLE disease activity, especially related with SLE renal disease activity. IL-37 is an
important cytokine in the control of SLE pathogenesis by suppressing the production of inflammatory cytokines. Thus,
IL-37 may provide a novel research target for the pathogenesis and therapy of SLE.
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The interleukin (IL)-1 family of cytokines possesses a
variety of immunoregulatory properties in response to
inflammation and autoimmune diseases [1]. As the
members of the IL-1 family, seven cytokines (IL-1α,
IL-1β, IL-18, IL-33, IL-36α, IL-36β and IL-36γ) act as
agonists, and two are classified as naturally occurring re-
ceptor antagonists (IL-1Ra and IL-36Ra) [2,3]. IL-37, the
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unless otherwise stated.as IL-1 family member 7 (IL-1F7), is a fundamental
inhibitor of innate immunity [4].
Recent studies demonstrated that anti-inflammatory
cytokines TGF-β, IL-10, several toll-like receptor (TLR)
ligands and pro-inflammatory cytokines such as IL-1β,
TNF-α, IFN-γ and IL-18 induce IL-37 production in per-
ipheral blood mononuclear cells (PBMCs) [4,5]. However,
over-expressed human IL-37 suppressed the TLR-induced
pro-inflammatory cytokines in a mouse macrophage
RAW cell line, in human monocyte cell line THP-1
and in alveolar epithelial A549 cells [1,4]. In vivo, mice
transgenic for IL-37 (IL-37tg) exhibited markedly reduced
manifestations of DSS colitis, ischemia–reperfusion injury
and obesity-induced inflammation [6-8]. Compared toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Demographic and clinical characteristics at the





Age (years) 30.5 ± 8.02 (18-54) 31.8 ± 9.57 (19-58)
Sex (female/male) 59/7 37/4
Disease duration (years) 2.0 ± 1.12 -
Arthritis n (%) 3 (4.5) -
Renal diseases n (%) 40 (60.6) -
Fever n (%) 13 (19.7) -
Neurological disorder n (%) 1 (1.5) -
Leukopenia n (%) 11 (16.7) -
Thrombocytopenia n (%) 8 (12.1) -
Anti-ds-DNA antibody n (%) 39 (59.1) -
Anti-Smith antibody n (%) 30 (45.5) -
Anti-AnuA antibody n (%) 20 (30.3) -
Anti-rRNP antibody n (%) 11 (16.7) -
ESR 29.2 ± 27.80 -
Low C3 n (%) 33 (50.0) -
Low C4 n (%) 29 (43.9) -
IgG (g/L) 16.2 ± 5.63 -
IgM (g/L) 1.21 ± 0.64 -
IgA (g/L) 2.33 ± 1.09 -
SLEDAI (2-14) 6.34 ± 3.26 -
Except where otherwise indicated, values are expressed as mean ± standard
deviation. There were no significant differences between patients with SLE and
healthy donors in terms of age and sex. Anti-ds-DNA antibody, anti-double
stranded DNA antibody; Anti-Smith antibody, anti-smith-antibody; Anti-AnuA
antibody, anti-nucleosome antibody; Anti-rRNP antibody, Anti-Ribosomal RNP
Antibody; ESR, erythrocyte sedimentation rate; C3, complement 3; C4,
complement 4; IgG, Immunoglobulin G; IgM, Immunoglobulin M; IgA,
Immunoglobulin A; SLE, systemic lupus erythematosus; SLEDAI, SLE disease
activity index.
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sues from patients with rheumatoid arthritis [4]. Similar
studies have found that IL-37 was not detected in the nor-
mal colonic mucosa, but in the inflamed mucosa of IBD
patients [9]. These findings tend to imply that IL-37 medi-
ates a negative feedback mechanism to suppress excessive
inflammation.
Systemic lupus erythematosus (SLE) is an autoimmune
and inflammatory disease characterized by the activation
of T and polyclonal B lymphocytes. The activation of B
cells produces numerous auto-antibodies and form im-
mune complexes with variety antigens, which result in
tissue and organ damage [10]. Cytokines collectively play
key roles in the regulation of systemic inflammation,
local tissue damage and immunoreactions [11]. Abnor-
mal release various cytokines have been identified in
SLE patients and animal models both in vitro and
in vivo [12]. Abundant studies have demonstrated that
pro- and anti-inflammatory cytokines, including TNF-α,
IL-1β, IL-6 and IL-10, play crucial pathogenic roles in
the disease of SLE [12,13]. Although the serum IL-37
levels have been found to be elevated in active patients
with SLE [14], its causal relationship with disease activity
and their clinical association and disease manifestations
in SLE is still unclear, especially the regulations of
cytokines expression by IL-37 in SLE PBMCs remain to
be studied.
In present study, we compared expressions of IL-37
mRNAs in PBMCs and serum IL-37 protein levels in
SLE patients with healthy controls. In addition, we deter-
mined the correlation of serum IL-37 levels with disease
activity and clinical manifestations in SLE, investigated
the effect of IL-37 on the expressions of cytokine TNF-α,
IL-1β, IL-6 and IL-10.
Materials and methods
Patients and controls
The study was approved by the Review Board for Peking
University Shenzhen Hospital in Shenzhen, People’s
Republic of China. Sixty-six patients who satisfied the
revised classification criteria of the ACR for SLE [15] were
recruited from the Rheumatology Department, Peking
University Shenzhen Hospital. Forty-one age- and sex-
matched volunteers were recruited from Peking University
Shenzhen Hospital as healthy controls. Informed consent
was obtained from recruited subjects. Individuals with
other rheumatic diseases, infections or malignant tumors
were excluded from the study.
SLE patients’ laboratory tests containing anti-double
stranded (ds) DNA antibody, anti-nucleosome antibody
(AnuA), anti-smith antibody (Smith), Anti-Ribosomal
RNP Antibody (rRNP), erythrocyte sedimentation rate
(ESR), complement 3 (C3), complement 4 (C4), IgG,
IgM and IgA were performed. Clinical data from eachpatients were recorded. Lupus disease activities were
assessed by using the Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI) score [16]. Active lupus
disease was defined as SLEDAI score ≥ 6 [17,18]. Demo-
graphic characteristics of the SLE patients and healthy
controls are listed in Table 1.
Blood samples
Fasting venous bloods (4 ml) were collected and processed
within three hours. PBMCs were isolated from patients
and healthy controls by a Ficoll-Paque Plus (TBDscience,
China) density gradient centrifugation for cell culture or
stored at -80°C until RNA extraction. Serum samples were
stored at -80°C until cytokine were determined.
Recombinant human IL-37 protein
Cloning
The gene for interleukin 37 gene (homo species) was
amplified from cDNA of peripheral blood mononuclear
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CACAAGTCCA-3′ and 5′- CCCAAGCTTCTAATCGC
TGACCTCACT-3′. The PCR fragments were double
digested with restriction endonucleases (Takara, China)
and ligated into the prokaryotic expression vectors.
Expression
The fusion proteins were expressed in a stable prokaryotic
expression system. Briefly, ligation mixtures (as described
above) were transformed into E. coli Trans (T1) compe-
tent cells. The positive clones were identified by colony
PCR. The plasmids of positive clones were then sequenced
by Sanger method. The plasmid that was 100% identify
with the published sequence (GenBank:AF167368) was
transformed into expression host E. coli competent cells.
The induced and uninduced cultures were analyzed by
SDS-PAGE to identify the expression of recombinant
protein.
Purification and characterization of IL-37
The harvested cells were resuspended in NaCl- Tris-HCl
buffer, sonicated in an ice bath, 12000 rpm centrifuged
30 min, then the supernatant were collected. The super-
natant were added to His Trap HP, 1 ml column (GE)
that had been equilibrated with NaCl-Tris-HCl buffer.
Different concentrations of imidazole buffer were used
to elute the recombinant protein. Collected target pro-
tein peaks were examined by SDS-PAGE electrophoresis
and immunoblot analysis using anti-human IL-37 anti-
bodies (Abcam, UK). The eluted recombinant proteins
were dialyzed in PBS at 4°C for overnight. The concen-
trations were detected by Brandford methods, and the
recombinant protein was stored at -20°C.
Cell culture condition
Culture medium, consisted of RPMI 1640 (Hyclone,
Thermo, USA) supplemented with 10% Fetal Calf Serum
(Sijiqing, Zhejiang, China), 100 IU/ml penicillin and
100 μg/ml streptomycin (Beyotime, China), respectively.
Whole PBMCs were cultured in 24 well, flat-bottomed
plates (5 × 105 cells/ml/well) for 24 h, PBMCs were stim-
ulated with or without human recombinant IL-37 at
100 ng/ml for 6 h, total RNAs were extracted, and cyto-
kine transcriptions were analyzed by RT-PCR. PBMCs
were stimulated with or without human recombinant
IL-37 at 100 ng/ml for 24 h, and then incubated further
with LPS (1 μg/ml) for 6 h, culture supernatants were
harvested and froze at -80°C for later cytokine analysis
by ELISA.
RNA extraction and real-time polymerase chain reaction
(RT-PCR)
Total RNA was extracted from PBMCs with Trizol
(Invitrogen, Carlsbad, CA, USA) according to themanufacturer’s instructions. Then the quantity and
purity of RNA was determined by absorbance on a
FilterMax F5 Multi-Mode Microplate Reader (Sunnyvale,
California, USA) at 260 nm and 280 nm. Samples with
ratios from 1.8 to 2.0 were accepted for next reverse tran-
scription reaction. cDNAs were prepared by using the
iScript™ cDNA Synthesis kit (Bio-Rad, USA). PCR primers
(Generay, Shanghai, China) used for RT-PCR were as
follows: for IL-37, sense: 5′-AGTGCTGCTTAGAAGAC
CCGG-3′ and 5′-AGAGTCCAGGACCAGTACTTTGT
GA-3′(reverse); TNF-α, sense: 5′-ACCTCTCTCTAATCA
GCCCTCT-3′ and anti-sense: 5′-GGGTTTGCTACAAC
ATGGGCTA; IL-1β, sense: 5′- CCACAGACCTTCCAG
GAGAAT-3′ and anti-sense: 5′-GTGCACATAAGCCT
CGTTATCC-3′; IL-6, sense: 5′-AGCCACTCACCTCTTC
AGAAC-3′ and anti-sense: 5′-ACATGTCTCCTTTCTCA
GGGC-3′; IL-10, sense: 5′-CTGCCTAACATGCTTCGA
GATC-3′ and anti-sense: 5′-TCCTCCAGCAAGGACTC
CTTT-3′; β-actin, 5′-CCTGACTGACTACCTCATGAA
G-3′ and anti-sense: 5′-GACGTAGCACAGCTTCTCCT
TA-3′. RT-PCR amplification reactions were prepared with
the SYBR Green PCR kit (Bio-rad, USA) and performed
using the 7500 fast Real-Time PCR system (Applied
Biosystems, USA). PCR products were verified by melting
curve analysis. Relative mRNA levels of target genes were
calculated by the 2-ΔΔct method.
Enzyme-linked immunosorbent assay (ELISA)
Serum IL-37 levels and cell culture supernatant IL-37,
TNF-α, IL-1β, IL-6 and IL-10 levels were determined by
ELISA following the manufacturer’s instructions. IL-37
was quantified using ELISA reagent kits purchased from
AdipoGen (San Diego, CA, USA). Detection of the cyto-
kines TNF-α, IL-1β, IL-6 and IL-10 were accomplished
using the eBioscience kit (San Diego, CA, USA).
Statistical analysis
Data were expressed as mean (±SEM) or median (range)
and analysed by Graphpad Prism V.5.00 software
(GraphPad Software, San Diego CA, USA). Comparisons
between groups were made using nonparametric Mann-
Whitney U-test. Spearman correlation test was used to
assess the association between serum IL-37 levels and
different variables. P values under 0.05 were considered
statistically significant.
Results
IL-37 mRNAs and serum protein levels were higher in
patients with SLE compared with healthy controls
The expressions of IL-37 mRNAs in PBMCs and Serum
IL-37 protein levels from 66 SLE patients and 41 age-
and sex-matched healthy controls (HC) were measured
by RT-PCR and ELISA, respectively. SLE patients and
healthy controls did not reveal significant differences in
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shown in Figure 1A, SLE patients had significantly higher
IL-37 mRNAs levels than healthy controls (P = 0.0009).
Figure 1B also displayed significant elevation of serum
IL-37 protein levels in patients with SLE compared with
healthy controls (P = 0.0002), indicating that IL-37 prob-
ably participated in the mediation of pathogenesis of SLE.
IL-37 mRNAs and serum protein levels were higher in SLE
patients with active disease compared with those with
inactive disease
We next investigated whether IL-37 was related to dis-
ease activity in SLE patients. We divided SLE patients
into active groups (SLEDAI score ≥ 6) and inactive groups
(SLEDAI score < 6) according to SLEDAI. As seen in
Figure 2A and B, significant differences were viewed in
IL-37 mRNAs and protein levels between patients with
active and those with inactive diseases (P = 0.0218,
P = 0.0023, respectively). In the meantime, patients with
active disease displayed higher IL-37 mRNAs and serum
IL-37 protein levels than healthy controls (P < 0.0001,
P < 0.0001, respectively). However, we did not observe the
differences of IL-37 mRNAs and protein levels between
patients with inactive disease and healthy controls
(Figure 2). Thus, we speculated that IL-37 probably
was associated with disease activity of SLE.
Correlation between IL-37 levels and SLEDAI as well as
laboratory values
To further survey the relationship between serum IL-37
protein levels and disease activity, we next detected
correlations between IL-37 and SLEDAI as well as la-
boratory values such as anti-dsDNA, smith, AnuA, rRNP
antibody, IgG, IgM, IgA, ESR, C3 and C4. A significantly
positive correlation was observed between serum IL-37
levels and SLEDAI (r = 0.3416, P = 0.005, Figure 3A).
There was a negative correlation between serum IL-37
and C3 levels (r = -0.3687, P = 0.0023, Figure 3B), as well
as C4 levels (r = -0.3175, P = 0.0094, Figure 3C). NoFigure 1 Comparison of IL-37 mRNAs and protein levels between SLE
(n = 66) and healthy controls (HC, n = 41) were determined by RT-PCR. Resu
box) and 10th, 25th, 75th, and 90th percentiles (bottom bar, bottom of box,
SLE patients (n = 66) and healthy controls (HC, n = 41) were determined by
controls. Horizontal lines indicate median values. Mann-Whitney U-test andsignificant correlations were found between serum IL-37
levels and anti-dsDNA, smith, AnuA, rRNP antibody,
IgG, IgM, IgA and ESR, respectively (data not shown).
Association of serum IL-37 protein levels with clinical
features in SLE
To assess associations between serum IL-37 protein
levels and clinical manifestations, serum IL-37 protein
levels were compared among patients with and those
without certain clinical features as well as healthy con-
trols. We identified that no significant differences in
serum IL-37 protein levels between patients in the pres-
ence of malar rash, serositis, arthritis, fever, neurological
disorder, anemia, leucopenia and thrombocytopenia, and
patients in the absence of the above-mentioned clinical
manifestations (data not shown). Nevertheless, we dis-
cerned that serum IL-37 levels were significantly higher
in patients with renal disease compared with those with-
out these manifestations (P = 0.033, Figure 4), further-
more the patients without renal disease did not show
significant higher serum IL-37 level than healthy con-
trols (Figure 4), illustrating that IL-37 probably related
with renal disorder in SLE.
IL-37 inhibits the productions of inflammatory cytokines
in PBMCs of SLE patients
IL-37 has been reported as an inhibitor of innate immun-
ity [4]. To assess whether IL-37 had a similar capacity to
regulate the expressions of inflammatory cytokines in-
volved in the pathogenesis of SLE. We have expressed
and purified recombinant human IL-37 protein (Additional
file 1). Initially, we evaluated the effects of IL-37 on LPS-
induced cytokines expression in PBMCs. The cells were
pre-incubated with or without different concentrations of
IL-37 (0 ng/ml, 1 ng/ml, 10 ng/ml, 100 ng/ml and 200 ng/
ml) for 6 h, and then incubated further with LPS (1 μg/ml)
for 6 h. IL-37 significantly reduced the LPS-induced TNF-
α, IL-6 and IL-1β mRNA expressions at 100 ng/ml and
200 ng/ml (Additional file 2A-C), but the expression ofand HC. (A) Expressions of IL-37 mRNAs in PBMCs from SLE patients
lts are depicted as box plots, with median (horizontal line within each
top of box, and top bar, respectively). (B) Serum IL-37 protein levels in
ELISA. Each symbol represents an individual SLE patients and healthy
associated P values are indicated.
Figure 2 Comparison of IL-37 mRNAs and protein levels among SLE patients with active disease and inactive disease as well as HC.
(A) Levels of IL-37 mRNAs in PBMCs from SLE patients, distributed according to disease activity (i.e. active (n = 36) versus inactive (n = 30)), were
compared by RT-PCR with those from healthy controls (HC, n = 41). Results are depicted as box plots, with median values, 25th and 75th quartile
and the range of values. (B) Serum IL-37 protein levels in SLE patients, distributed according to disease activity (i.e. active (n = 36) versus inactive
(n = 30)), were compared by ELISA with those from healthy controls (HC, n = 41). Each symbol represents an individual patient. Horizontal lines
indicate median values. Mann-Whitney U-test and associated P values are indicated. NS, no significant.
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To further address the effect of IL-37 on cytokines in
PBMCs from SLE patients, IL-37 (100 ng/ml) was added
to the cultures of PBMCs from SLE and healthy controls
separately. Our experiments showed that the expressions
of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β
mRNAs in PBMCs of SLE patients were significantly
suppressed by IL-37 (Figure 5A,C,E). Meanwhile, IL-37
also markedly reduced the secretions of TNF-α, IL-6
and IL-1β in PBMCs of SLE patients (Figure 5B,D,F).
By contrast, no change of IL-10 mRNAs and protein
levels were detected (Figure 5G and H). Interestingly,
these cytokines expressions in PBMCs of healthy con-
trols were unaffected by treatment with IL-37 (data not
shown).
Discussion
Although IL-37 mRNA expression and serum protein
level has been demonstrated to be higher in active SLE
patients [14], but information with regard to its clinical
association and disease manifestation is lacking. Our
results provide a detailed analysis of IL-37 expression inFigure 3 Correlation of serum IL-37 levels with SLEDAI as well as labo
Serum IL-37 levels were positively correlated with SLEDAI. (B) Negative relatio
relationship was observed between serum IL-37 levels and C4. The correlationSLE patients (SLEDAI ≥ 6, active SLE and SLEDAI < 6,
inactive SLE) and healthy controls. We demonstrated
that IL-37 mRNAs expressions and serum protein levels
were higher in 66 patients with SLE than in 41 healthy
controls (Figure 1). Further investigation revealed that
IL-37 mRNAs and protein levels were significantly
higher in 36 patients with active diseases than in 30 pa-
tients with inactive diseases and in 41 healthy controls.
However, there is no difference between inactive diseases
and healthy controls (Figure 2). In order to further
proved the relationship between IL-37 expression and
SLE laboratory values, we made efforts to analyze the
correlation between serum IL-37 protein levels and sev-
eral laboratory values. Our novel data suggested that
serum IL-37 levels were negatively correlated with C3
and C4 (Figure 3), but it lacked association with other
laboratory values (anti-dsDNA, smith, AnuA, rRNP anti-
body, IgG, IgM, IgA and ESR) (data not shown). Thus,
our findings implied that the expression of IL-37 is cor-
related with activity of SLE, and IL-37 probably involved
in the mediation of the disease activity. In patients with
SLE, skin involvement, arthritis and renal disorder are
very common manifestations. We showed that noratory values. Each symbol represents an individual SLE patient. (A)
nship was observed between serum IL-37 levels and C3. (C) Negative
s were evaluated with Spearman’s non-parametric test.
Figure 4 Elevated serum IL-37 levels in SLE patients with renal
disease. Serum IL-37 levels exhibited a significant elevation in patients
with renal involvement (n = 40) relative to patients without renal
disease (n = 26) as well as healthy control (HC, n = 41). Each symbol
represents an individual patient or healthy control. Horizontal lines
indicate median values. Mann-Whitney U-test and associated P values
are indicated. NS, no significant.
Figure 5 IL-37 inhibits the expression of inflammatory cytokines in PB
healthy controls (n = 41) were stimulated with IL-37 (100 ng/ml) for 6 hour
and IL-6 (E) IL-10 (G) mRNAs by RT-PCR. Box plots show the median values, 2
with IL-37 (100 ng/ml) for 24 hour, and then incubated further with LPS (1 μg
and IL-10 (H) levels using enzyme-linked immunosorbent assay (ELISA). Each s
indicate median values. Actual P values are shown in the graph. NS, no signifi
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between the patients who had malar rash, serositis, arth-
ritis, fever, neurological disorder, anemia, leucopenia and
thrombocytopenia and the patients who absented the
above-mentioned clinical manifestations (data not shown).
Surprisingly, serum IL-37 levels were significantly higher
in patients with renal disease compared with patients
without renal involvement together with healthy controls
(Figure 4). In summary, our experiments demonstrated
that the expression levels of IL-37 correlated with the
disease activity, laboratory values and clinical manifes-
tations of SLE.
Imbalances between pro- and anti-inflammatory cyto-
kines are hallmarks of the pathogenesis of SLE [19,20]. It
has been demonstrated that pro-inflammatory cytokines
TNF-α, IL-1β, IL-6 and cytokine IL-10 levels are signifi-
cantly elevated in the serum of SLE patients and correl-
ate with disease activity [13,21,22]. In particular, the
expressions of TNF-α, IL-6 and IL-10 are markedly ele-
vated in SLE patients with lupus nephritis [20-22]. Pub-
lished data have shown that blocking these cytokines
significantly improved the development of SLE [23-26].
Uppal SS et al showed that nine SLE patients treated
with anti-TNF-α monoclonal antibody, five patients
showed improvement in disease activity (SLEDAI) [24].
Two very small uncontrolled studies of three and four
SLE patients suggested that blocking IL-1 signaling might
have beneficial effects on lupus-related manifestationsMCs of patients with SLE. PBMCs from SLE patients (n = 66) and
, the total RNAs were extracted and analyzed for TNF-α (A), IL-1β (C)
5th and 75th quartile and the range of values. The cells were stimulated
/ml) for 6 h, supernatants were examined for TNF-α (B), IL-1β (D), IL-6 (F)
ymbol represents an individual patient or healthy control. Horizontal lines
cant.
Ye et al. Journal of Translational Medicine 2014, 12:69 Page 7 of 8
http://www.translational-medicine.com/content/12/1/69[24]. In addition, SLE patients with tocilizumab (anti-IL-6
receptor antibody) treatment resulted in significant clinical
improvement, especially in SLE patients with arthritis [25].
Another study found that administration of anti-IL-10
monoclonal antibody (21 consecutive days) to six patients
with moderate lupus (an open study) resulted in healing of
arthritis and cutaneous lesions [26].
In our present study, the expressions of TNF-α, IL-1β,
IL-6 and IL-10 were significantly increased in PBMCs of
SLE patients than in PBMCs from healthy controls.
Interestingly, our result also showed that the expression
of IL-37 was correlated with the activity of disease in
SLE. What are the functions of a fundamental innate im-
munity inhibitor IL-37 [4] in SLE? To answer the ques-
tion, recombinant purified IL-37 was used to stimulate
PBMCs from SLE patients and health controls. Our
study is the first to reveal that IL-37 could effectively
decrease the productions of pro-inflammatory cytokines
TNF-α, IL-6 and IL-1β (Figure 5A-F), whereas the pro-
ductions of cytokine IL-10 were unaffected in PBMCs of
SLE patients (Figure 5G-H). Researcher showed that
IL-37 can be up-regulated by cytokines IL-1β, TNF-α
and IL-10 [4,5], indicating these cytokines act as positive
feedback loops for up-regulation of IL-37 production.
Therefore, it is reasonable to explain the correlation
between higher activity of disease and the higher expres-
sion levels of IL-37 in SLE. Recently, IL-37 has been
shown to inhibit the production of pro-inflammatory
cytokines TNF-α, IL-1β and IL-6 in PBMCs in vitro [4].
Together with this result, the down regulation of pro-
inflammatory cytokines in our experiments imply that
IL-37 may play an important role in the inhibition of
inflammatory response in SLE, the up regulation of
IL-37 by SLE immune reaction may be the result of in-
flammatory diseases self-limiting. It has been shown that
the expression of IL-10 in PBMCs was unaffected by
treatment with siIL-37 [4], which was consistent with
our finding. These data demonstrated that IL-37 acts as
an inhibitor of inflammatory responses in SLE disease,
but this function does not extend to cytokines IL-10.
Interestingly, the pro-inflammatory cytokine produc-
tions in PBMCs of healthy controls and inactive disease
with SLE patients were unaffected by treatment with IL-37
(Figure 5), suggesting that anti-inflammatory actions of
IL-37 are only in the inflammatory phase and active dis-
ease conditions of SLE. Nold et al. showed that IL-37 sup-
presses the phosphorylation of p38 MAPK [4], which are
known to be involved in the pathogenesis of SLE and con-
tributes to several pro-inflammatory signaling cascades
[27]. It has been demonstrated that inhibition of p38
MAPK activation reduced serum TNF-a, IL-1β and IL-6
levels and attenuated SLE renal injury [28,29]. Thus, it is
plausible that down-regulation of several kinase activity by
IL-37, such as p38 MAPK, might result in reducedexpression of pro-inflammatory cytokines in PBMC during
inflammatory responses, which could lead to suppression
of excessive immune response, and protection of tissue
damage in SLE.
Conclusions
In summary, our study showed that the expressions of
IL-37 correlated with the disease activity of SLE. Mean-
while, it was likely to mediate a negative feedback mechan-
ism to suppress excessive inflammation in SLE, especially
in renal disease of SLE. Furthermore, we demonstrated
that the expressions of pro-inflammatory cytokines TNF-
α, IL-6 and IL-1β were suppressed by IL-37 in active SLE
patients. These observations implicate that IL-37 probably
played an important role in the inhibition of pathogenesis
of SLE. Future efforts need to define the regulatory
mechanisms of IL-37 in the mediation of immune
reaction of SLE.
Additional files
Additional file 1: Recombinant human IL-37 fusion protein. (A)
Cloning of human IL-37 gene. Human IL-37 gene was amplified using
Taq polymerase and the PCR product was found about 522 bp. Molecular
weight makers and sizes were shown on the left. Lane 1-5: Positive clones
of human IL-37 gene; Lane 6: negative control. (B) Expressions of human
IL-37 in E. coli Transetta (DE3) cells. The expression of human IL-37 was
induced with IPTG. Induced and uninduced cultures were compared by
SDS-PAGE. Molecular weight makers and sizes are shown on the left.
Lane 1: uninduced cells; Lane 2 and 3: induced cells respectively. (C)
Gel electrophoresis of purified human IL-37. Molecular weight makers
and sizes are shown on the left. (D) Western blot analysis using monoclonal
antibodies (mAb) against the human IL-37.
Additional file 2: Dose-dependent effects of IL-37 on inflammatory
cytokines mRNA expression in PBMCs of healthy donors. PBMCs of
healthy donors were stimulated for 6 h with different concentrations of
IL-37, and then incubated further with or without LPS (1 μg/ml) for 6 h.
The TNF-α (A), IL-6 (B), IL-1β (C) and IL-10 (D) mRNAs expression was analyzed
by real-time polymerase chain reaction (PCR). Values are the mean ± SEM
(n = 3). *P < 0.05; **P < 0.01.
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